Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

252 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.
Dickler MN, Saura C, Richards DA, Krop IE, Cervantes A, Bedard PL, Patel MR, Pusztai L, Oliveira M, Cardenas AK, Cui N, Wilson TR, Stout TJ, Wei MC, Hsu JY, Baselga J. Dickler MN, et al. Among authors: bedard pl. Clin Cancer Res. 2018 Sep 15;24(18):4380-4387. doi: 10.1158/1078-0432.CCR-18-0613. Epub 2018 May 23. Clin Cancer Res. 2018. PMID: 29793946 Free PMC article. Clinical Trial.
Luminal-B breast cancer and novel therapeutic targets.
Tran B, Bedard PL. Tran B, et al. Among authors: bedard pl. Breast Cancer Res. 2011;13(6):221. doi: 10.1186/bcr2904. Epub 2011 Nov 30. Breast Cancer Res. 2011. PMID: 22217398 Free PMC article. Review.
Management of small HER2 overexpressing tumours.
Templeton A, Ocaña A, Seruga B, Vera-Badillo F, Carlsson L, Bedard P, Amir E. Templeton A, et al. Breast Cancer Res Treat. 2012 Nov;136(1):289-93. doi: 10.1007/s10549-012-2236-9. Epub 2012 Sep 6. Breast Cancer Res Treat. 2012. PMID: 22956007
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).
Richter S, Bedard PL, Chen EX, Clarke BA, Tran B, Hotte SJ, Stathis A, Hirte HW, Razak AR, Reedijk M, Chen Z, Cohen B, Zhang WJ, Wang L, Ivy SP, Moore MJ, Oza AM, Siu LL, McWhirter E. Richter S, et al. Among authors: bedard pl. Invest New Drugs. 2014 Apr;32(2):243-9. doi: 10.1007/s10637-013-9965-4. Epub 2013 May 5. Invest New Drugs. 2014. PMID: 23645447 Free PMC article. Clinical Trial.
A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors.
Diaz-Padilla I, Hirte H, Oza AM, Clarke BA, Cohen B, Reedjik M, Zhang T, Kamel-Reid S, Ivy SP, Hotte SJ, Razak AA, Chen EX, Brana I, Wizemann M, Wang L, Siu LL, Bedard PL. Diaz-Padilla I, et al. Among authors: bedard pl. Invest New Drugs. 2013 Oct;31(5):1182-91. doi: 10.1007/s10637-013-0001-5. Epub 2013 Jul 17. Invest New Drugs. 2013. PMID: 23860641 Free PMC article. Clinical Trial.
Personalized medicine for metastatic breast cancer.
Chen TW, Bedard PL. Chen TW, et al. Among authors: bedard pl. Curr Opin Oncol. 2013 Nov;25(6):615-24. doi: 10.1097/CCO.0000000000000015. Curr Opin Oncol. 2013. PMID: 24097103 Review.
A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin.
Brana I, Ocana A, Chen EX, Razak AR, Haines C, Lee C, Douglas S, Wang L, Siu LL, Tannock IF, Bedard PL. Brana I, et al. Among authors: bedard pl. Invest New Drugs. 2014 Dec;32(6):1269-77. doi: 10.1007/s10637-014-0159-5. Epub 2014 Sep 12. Invest New Drugs. 2014. PMID: 25213162 Clinical Trial.
252 results